SSA
VYNE icon

Schonfeld Strategic Advisors’s VYNE Therapeutics VYNE Stock Holding History

Schonfeld Strategic Advisors’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-161,951
Closed -$267K – 2618
2025
Q2 		$267K Buy
161,951
+76,973
+91% +$100K ﹤0.01% 1722
2025
Q1 		$134K Sell
84,978
-91,680
-52% -$226K ﹤0.01% 1990
2024
Q4 		$592K Buy
176,658
+8,058
+5% +$21.1K ﹤0.01% 1326
2024
Q3 		$317K Sell
168,600
-47,623
-22% -$90.3K ﹤0.01% 1630
2024
Q2 		$426K Sell
216,223
-3,577
-2% -$8.92K ﹤0.01% 1558
2024
Q1 		$675K Buy
+219,800
New +$474K ﹤0.01% 1363
2021
Q2 		– Sell
-969
Closed -$119K – 2348
2021
Q1 		$119K Sell
969
-73
-7% -$10.6K ﹤0.01% 1610
2020
Q4 		$119K Sell
1,042
-2,037
-66% -$256K ﹤0.01% 1425
2020
Q3 		$368K Sell
3,079
-2,189
-42% -$255K 0.01% 1015
2020
Q2 		$657K Buy
+5,268
New +$713K 0.02% 721
2018
Q4 		– Sell
-694
Closed -$493K – 1247
2018
Q3 		$493K Hold
694
– – 0.02% 580
2018
Q2 		$406K Buy
+694
New +$539K 0.02% 575

Other funds holding VYNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Schonfeld Strategic Advisors's VYNE Position: Q3 2025 in Review

Schonfeld Strategic Advisors sold out of VYNE Therapeutics (VYNE) in Q3 2025, closing a stake of 161,951 shares — an estimated $267K sold.

Schonfeld Strategic Advisors first reported a position in VYNE in Q2 2018 and held it in 12 quarters. The position peaked at $675K in Q1 2024. 36 funds tracked by Wall St. Rank hold VYNE as of Q3 2025.

  • Schonfeld Strategic Advisors reported no remaining VYNE Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 161,951 VYNE Therapeutics shares in Q3 2025, an estimated $267K.
  • Schonfeld Strategic Advisors first reported a position in VYNE Therapeutics in Q2 2018 and held it in 12 quarters.
  • Schonfeld Strategic Advisors's VYNE Therapeutics position peaked at $675K in Q1 2024.
  • 36 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.